Abstract Details

Title Comparative Efficacy of BEAM EEG and MMSE in Early Detection of Mild Cognitive Impairment: A Pilot Study

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P8 - Poster Session 8 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-010

Objective To evaluate the effectiveness of BEAM^TM in predicting MCI by analyzing the correlation between BEAM^TM biomarkers and age, compared to MMSE scores and expected values for MCI patients.

Background Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD and its precursor state, mild cognitive impairment (MCI), is often screened for using tools such as the Mini-Mental State Examination (MMSE). However, its efficacy at identifying early stages of MCI is inconsistent. BEAM^TM (Biomarker-based Electrophysiology for Advanced Monitoring) is a novel platform utilizing neurotechnology to evaluate electroencephalograms (EEGs) administered under neurocognitive testing to identify event-related potential (ERPs) that are early biomarkers of MCI.

Design/Methods A retrospective chart review was conducted at Hawaii Pacific Neuroscience for patients who underwent BEAM^TM testing from March to June 2024. We identified 104 patients diagnosed with MCI based on current MMSE scores who completed EEG testing under resting state (eyes-open and eyes-closed, 5-minutes each) and three scenarios: Auditory Oddball (AO), 3-Choice Vigilance Test (3CVT), and Standard Image Recognition (SIR).

Results Mean MMSE was 24.47 and negatively correlated with age (r = -0.31, p < 0.05). Resting state peak alpha scores were weakly indirectly correlated with age (r = -0.20, p < 0.05). AO N1 peak latency exhibited a stronger direct correlation with age ( r = 0.34, p < 0.05). AO P300 max latency was weakly directly correlated with age (r = 0.23, p < 0.05). 3CVT P2 peak latency was positively correlated with age (r = 0.40, p < 0.05). Accuracy was indirectly correlated with age in 3CVT (r = -0.24, p < 0.05) and SIR (r = -0.33, p < 0.05).

Conclusions BEAM^TM parameters, particularly AO N1 peak latency and 3CVT P2 peak latency, can be useful biomarkers for cognitive decline. The significant correlations between BEAM^TM biomarkers and age highlight its potential in clinical settings for diagnosing MCI.

Authors/Disclosures
Janette Bow-Keola PRESENTER	Miss Bow-Keola has nothing to disclose.
Daniel Vodak	Mr. Vodak has nothing to disclose.
Kai Y. Moriyama, Undergraduate Student	Mr. Moriyama has nothing to disclose.
Yun Shwe-kya Pine, Student	Miss Pine has nothing to disclose.
Kylie C. Yamauchi	Ms. Yamauchi has nothing to disclose.
Michael Read, MD student	Mr. Read has nothing to disclose.
Shay Nakahira	Ms. Nakahira has nothing to disclose.
Kirra Borrello	Miss Borrello has nothing to disclose.
D-Dré Wright	Ms. Wright has nothing to disclose.
Anita Cheung, MPH	Miss Cheung has nothing to disclose.
Ryan Nakamura	Mr. Nakamura has received personal compensation for serving as an employee of Hawaii Health & Harm Reduction Center.
Chris K. Deng	Mr. Deng has nothing to disclose.
Enrique Carrazana (Neurelis, Inc.)	Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Hawaii-Biotech, CND Life Sciences, Apex Labs. Enrique Carrazana has stock in Neurelis, CND, Apex.
Amir H. Meghdadi, PhD (Advanced Brain Monitoring)	Dr. Meghdadi has received personal compensation for serving as an employee of Advanced Brain Monitoring. The institution of Dr. Meghdadi has received research support from National Institute of Health (NIH).
Kore K. Liow, MD, FACP (University of Hawaii, John Burns School of Medicine)	The institution of Dr. Liow has received research support from UCB. The institution of Dr. Liow has received research support from Livanova. The institution of Dr. Liow has received research support from Biogen. The institution of Dr. Liow has received research support from Novartis. The institution of Dr. Liow has received research support from Eisai. The institution of Dr. Liow has received research support from Engage Therapeutics. The institution of Dr. Liow has received research support from SK Lifescience. The institution of Dr. Liow has received research support from Cerevel. The institution of Dr. Liow has received research support from Xenon. The institution of Dr. Liow has received research support from NeuroDerm. The institution of Dr. Liow has received research support from Avanir. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Acadia. The institution of Dr. Liow has received research support from Prothena. The institution of Dr. Liow has received research support from SAGE. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Cyclerion.

��ɫ��

��ɫ��